Correspondence 0001493152-23-000165 from OKYO Pharma Ltd (OKYO) (CIK 0001849296) (OKYO)
OKYO Pharma Ltd (OKYO) (CIK 0001849296)
Date: Jan. 3, 2023 · CIK: 0001849296 · Accession: 0001493152-23-000165
AI Filing Summary & Sentiment
File numbers found in text: 333-268675
Letter
Re: OKYO Pharma LTD (the “Company”)
January 3, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
F Street, NE
Washington, D.C. 20549
Attn: Tyler Howes
Registration Statement on Form F-1/A
File No. 333-268675
Acceleration Request
Requested Date: January 5, 2023
Requested Time: 5:00 p.m., Eastern Standard Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the “Registration Statement”) to become effective on Thursday, January 5, 2023, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
[Signature Page Follows]
Securities and Exchange Commission, p. 2
January 3, 2023
Very truly yours,
ThinkEquity LLC
Show Raw Text
CORRESP
1
filename1.htm
January
3, 2023
Via
EDGAR
Securities
and Exchange Commission
Division
of Corporation Finance
100
F Street, NE
Washington, D.C. 20549
Attn:
Tyler Howes
Re:
OKYO Pharma LTD (the “Company”)
Registration Statement on Form F-1/A
File No. 333-268675
Acceleration Request
Requested Date: January 5, 2023
Requested Time: 5:00 p.m., Eastern Standard Time
Ladies
and Gentlemen:
In
accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), ThinkEquity LLC, as representative
of the several underwriters, hereby joins the Company in requesting that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the Registration Statement on Form F-1/A (File No. 333-268675) (the “Registration Statement”)
to become effective on Thursday, January 5, 2023, at 5:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.
Pursuant
to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus,
to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
We
have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities
Exchange Act of 1934, as amended, to the extent applicable.
[Signature
Page Follows]
Securities
and Exchange Commission, p. 2
January
3, 2023
Very truly yours,
ThinkEquity LLC
By:
/s/ Priynaka Mahajan
Name:
Priyanka Mahajan
Title:
Managing Director, Investment Banking
cc:
Gary Jacob, OKYO Pharma Ltd
Jeffrey Fessler, Sheppard, Mullin, Richter
& Hampton LLP
Anthony Marsico, Dorsey & Whitney LLP